| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Preclinical, clinical trial and other costs | |
$ | 2,142,229 | | |
$ | 1,261,720 | | |
$ | 3,339,263 | | |
$ | 2,293,001 | |
| Research and development personnel expense(1) | |
| 305,057 | | |
| 468,724 | | |
| 696,504 | | |
| 976,554 | |
| Research and development personnel
expense | |
| 305,057 | | |
| 468,724 | | |
| 696,504 | | |
| 976,554 | |
| General and administrative personnel expense(2) | |
| 628,330 | | |
| 445,620 | | |
| 1,302,167 | | |
| 964,409 | |
| General and administrative
personnel expense | |
| 628,330 | | |
| 445,620 | | |
| 1,302,167 | | |
| 964,409 | |
| Administrative and facilities expense(3) | |
| 875,167 | | |
| 905,960 | | |
| 1,459,839 | | |
| 1,657,658 | |
| Administrative and facilities
expense | |
| 875,167 | | |
| 905,960 | | |
| 1,459,839 | | |
| 1,657,658 | |
| Other income, net | |
| (16,865 | ) | |
| (71,698 | ) | |
| (29,450 | ) | |
| (154,915 | ) |
| Total | |
$ | 3,933,918 | | |
$ | 3,010,326 | | |
$ | 6,768,323 | | |
$ | 5,736,707 | |
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $8,613 and $45,583 for the three months ended
June 30, 2025 and 2024, respectively, and $55,333 and $76,704 for the six months ended June 30, 2025 and 2024, respectively. |
| |
|
|
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $122,655 and $40,309 for the three months
ended June 30, 2025 and 2024, respectively, and $245,310 and 79,180 for the six months ended June 30, 2025 and 2024, respectively,
and are net of reimbursements received from CorLyst, LLC. |
| |
|
|
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|